A - Study by Professor Shaker Mousa, Ph.D. focusing on the
effect of enoxaparin on TFPI endothelial cell release inhibition
induced by the bacterial endotoxin lipolysaccharide (LPS)
B - Study conducted by Drs. Michel Samama and Ismael Elalamy
of Hotel-Dieu Hospital in Paris, France, revealing that enoxaparin
has a process dependent inhibitory effect on Factor VIIa generation.
C - Study by Dr. Christian Boudier of Laboratoire d’Enzymologie
in Illkirch, France measuring the
change of fluorescence of ATIII upon its complexation with different
oligosaccharides and more particularly with decasaccharides
isolated from enoxaparin.
D - Study by Professor von Specht comparing the FGF2 inhibiting
effects of three groups of compounds: oligosaccharides with
the 1,6-anhydro ring structure, oligosaccharides without the
1,6-anhydro ring structure, and a third group consisting of
heparin, enoxaparin, and an ultra low molecular weight heparin